Rasha Aboelhassan: Khaled’s Journey – How Staging Changed His Lung Cancer Treatment
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“I met Khaled two years with his CT staging, showing 3 cm middle lobe right lung lesion and ipsilateral lymph node involvement, so that our MDT recommendations were upfront surgery for T1c N2 M0. adenocarcinoma histology no mutation.
Sergeant asked for PET-CT before surgery, whereas Khaled had different diagnoses, as PET-CT was showing contralateral LN 3 cm with SUV 10 changing diagnosis to T2N3 M0, which is not operable.
So that me and MDT members asked for bronchoscopy / mediastinoscopy and biopsy showing negative contralateral LN to give final staging, which was showing T1c N2 M0.
Khaled story was floating around when I read the International Association study of lung cancer reports ILCN about staging.
Staging is not just about the location of the tumor, it’s about prognosis and subsequently changing the plan of treatment and changing patients’ quality of life.”
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics. Rasha has been accepted as a member of staging and Prognostic Factors Group of lung cancer SPFG.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023